Table 2.
Study | Positive cases | Staining pattern | Antibody vendor/clone/dilution |
---|---|---|---|
Thompson et al. [3] | 5/60 (8%) | Focal, weak | BioGenex Labs/unspecified clone/1:40 |
Tse et al. [4] | 0/6 (0%) | None | Becton–Dickinson/My10/unspecified dilution |
Kuo et al. [5] | 0/5 (0%) | None | Dako/unspecified clone/1:50 |
Agaimy et al. [6] | 4/6 (67%) | Focal, weak | Immunotech/QBend10/1:200 |
Lasota et al. [7] | 13/13 (100%) | Variable | Dako/QBend10/1:150 |
Current | 5/5 (100%) | Mostly moderate, diffuse | Leica/QBend10/ready-to-use |
Current | 1/5 (20%) | Focal, weak | Ventana/QBend10/ready-to-use |
Total | 28/100 (28%) |